TS
VERV

Thomas Steyer’s Verve Therapeutics VERV Stock Holding History

Thomas Steyer’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-3,612,000
Closed -$40.6M – 163
2025
Q2 		$40.6M Buy
3,612,000
+2,700,000
+296% +$15.4M 0.17% 59
2025
Q1 		$4.17M Buy
+912,000
New +$6.11M 0.02% 84
2023
Q4 		– Sell
-211,293
Closed -$2.8M – 165
2023
Q3 		$2.8M Buy
+211,293
New +$3.4M 0.01% 104

Other funds holding VERV

GCM
Greenland Capital Management New York $812M AUM 45.54% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
BIG
Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

Thomas Steyer's VERV Position: Q3 2025 in Review

Thomas Steyer sold out of Verve Therapeutics (VERV) in Q3 2025, closing a stake of 3,612,000 shares — an estimated $40.6M sold.

Thomas Steyer first reported a position in VERV in Q3 2023 and held it in 3 quarters. The position peaked at $40.6M in Q2 2025. 6 funds tracked by Wall St. Rank hold VERV as of Q3 2025.

  • Thomas Steyer reported no remaining Verve Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Thomas Steyer sold 3,612,000 Verve Therapeutics shares in Q3 2025, an estimated $40.6M.
  • Thomas Steyer first reported a position in Verve Therapeutics in Q3 2023 and held it in 3 quarters.
  • Thomas Steyer's Verve Therapeutics position peaked at $40.6M in Q2 2025.
  • 6 funds tracked by Wall St. Rank held Verve Therapeutics as of Q3 2025.

Based on Farallon Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.